NO20072831L - Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil - Google Patents

Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil

Info

Publication number
NO20072831L
NO20072831L NO20072831A NO20072831A NO20072831L NO 20072831 L NO20072831 L NO 20072831L NO 20072831 A NO20072831 A NO 20072831A NO 20072831 A NO20072831 A NO 20072831A NO 20072831 L NO20072831 L NO 20072831L
Authority
NO
Norway
Prior art keywords
imidazo
compositions
pyridine compounds
methods related
compounds
Prior art date
Application number
NO20072831A
Other languages
English (en)
Inventor
Albert Palomer
Antonio Guglietta
Jose Luis Falco
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of NO20072831L publication Critical patent/NO20072831L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Nye imidazo[l,2-a]pyirdinforbindelser av generell formel (I): samt farmasøytisk akseptable salter derav; hvor Ri, R, Rog Rer som definert i kravene. Forbindelsene har spesifikk affinitet for GABA-reseptor og er derfor nyttige i behandling og forebyggelsen av sykdommer modulert av ai- og a-GABA-reseptorer.
NO20072831A 2004-11-11 2007-06-04 Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil NO20072831L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105698 2004-11-11
PCT/EP2005/055753 WO2006051063A1 (en) 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto

Publications (1)

Publication Number Publication Date
NO20072831L true NO20072831L (no) 2007-08-01

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072831A NO20072831L (no) 2004-11-11 2007-06-04 Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil

Country Status (24)

Country Link
US (1) US20080200473A1 (no)
EP (1) EP1814880B1 (no)
JP (1) JP2008519805A (no)
KR (1) KR20070084026A (no)
CN (1) CN101065377B (no)
AR (1) AR051626A1 (no)
AT (1) ATE421962T1 (no)
AU (1) AU2005303811A1 (no)
BR (1) BRPI0517796A (no)
CA (1) CA2585315A1 (no)
DE (1) DE602005012598D1 (no)
DK (1) DK1814880T3 (no)
ES (1) ES2321858T3 (no)
IL (1) IL182963A0 (no)
MX (1) MX2007005611A (no)
NO (1) NO20072831L (no)
PA (1) PA8652101A1 (no)
PE (1) PE20060967A1 (no)
PL (1) PL1814880T3 (no)
PT (1) PT1814880E (no)
RU (1) RU2007121864A (no)
TW (1) TWI357412B (no)
UY (1) UY29204A1 (no)
WO (1) WO2006051063A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
KR101119365B1 (ko) * 2006-05-31 2012-03-07 에프. 호프만-라 로슈 아게 아릴-4-에틴일-아이속사졸 유도체
BRPI0716583A2 (pt) * 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
AU2009249186B2 (en) 2008-05-19 2014-05-22 Sunovion Pharmaceuticals Inc. Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
US10478438B2 (en) 2008-10-16 2019-11-19 David Reed Helton Treatment of organophosphate exposure with ocinaplon
ES2403633T3 (es) * 2008-12-04 2013-05-20 Proximagen Limited Compuestos de imidazopiridina
IN2012DN04917A (no) * 2009-11-05 2015-09-25 Univ Notre Dame Du Lac
EP2617715A4 (en) * 2010-09-17 2014-02-26 Taisho Pharmaceutical Co Ltd GLYCINTRANSPORTERHEMMER
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
AU2024262043A1 (en) * 2023-04-24 2025-11-20 Shanghai SIMR Biotechnology Co., Ltd Imidazopyridine or imidazopyrazine compound, preparation method therefor, and pharmaceutical composition and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ATE62687T1 (de) * 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
US20040204443A1 (en) * 2003-01-27 2004-10-14 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Also Published As

Publication number Publication date
MX2007005611A (es) 2007-07-11
ATE421962T1 (de) 2009-02-15
WO2006051063A1 (en) 2006-05-18
CN101065377A (zh) 2007-10-31
JP2008519805A (ja) 2008-06-12
US20080200473A1 (en) 2008-08-21
TW200624432A (en) 2006-07-16
DE602005012598D1 (de) 2009-03-19
IL182963A0 (en) 2007-08-19
AR051626A1 (es) 2007-01-24
PL1814880T3 (pl) 2009-07-31
KR20070084026A (ko) 2007-08-24
PE20060967A1 (es) 2006-09-20
PT1814880E (pt) 2009-04-23
CA2585315A1 (en) 2006-05-18
EP1814880A1 (en) 2007-08-08
EP1814880B1 (en) 2009-01-28
AU2005303811A1 (en) 2006-05-18
TWI357412B (en) 2012-02-01
ES2321858T3 (es) 2009-06-12
CN101065377B (zh) 2011-07-27
BRPI0517796A (pt) 2008-10-28
PA8652101A1 (es) 2006-10-13
DK1814880T3 (da) 2009-05-18
UY29204A1 (es) 2006-01-31
RU2007121864A (ru) 2008-12-20

Similar Documents

Publication Publication Date Title
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
MX2007005611A (es) Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
NO20050417L (no) Azaindol kinase-inhibitorer
WO2006124490A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
NO20044882L (no) Acyl-4-karboksylfenylurinstoffderivater, deres fremstilling og anvendelse
WO2005123703A3 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2007058832A3 (en) Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
MX2009004096A (es) Metabolitos de talarozol.
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
NO20054852L (no) GFAT inhibitorer
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
EP1637521A4 (en) NEW TRICYCLIC HETEROCYCLIC COMPOUND
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application